Bristol-Myers’ Evotaz gets European approval to treat HIV-1 infection
Evotaz (atazanavir 300mg and cobicistat 150mg) tablets are approved for use in combination with other antiretroviral agents to treat HIV-1 infected adults without known mutations associated with resistance